The company announced the above during its FY25 first half financial presentation on February 26.
So far, 11 of its products are already registered with the US FDA.
Its US entry will be a digital and influencer-driven one, as it seeks to replicate its current strategy in regions like China.
As such, it has developed products for the US market based on the bestselling charts off Amazon and TikTok.
“Extensive market research was conducted, including an in-depth product and ingredient analysis of the top 100 best-selling products on Amazon and TikTok.
“This analysis has guided the development of new products designed to compete with existing competitors in the US market,” said the company.
Currently selling its supplements also under the name EZZ, the company said it would develop a US-specific brand to avoid confusion with Australia-made products and address pricing differences between markets.
“The Company’s comprehensive market entry plan, developed in collaboration with key agencies, is on track for execution in the second half of FY25.
“This initiative represents a significant step in EZZ’s growth strategy as it seeks to replicate the success of its digital and influencer-driven marketing efforts in other key regions.”
China is the company’s largest revenue stream. As of the first half of FY25, about 86 per cent of its sales, or AUD$23.4m (US$14.9m), came from Mainland China. This amount was also about 26.7 per cent higher as compared to last year’s sales of AUD$18.5m (US$11.7m).
In China, the company generates most of its sales from its own official online store on various e-commerce platforms like Douyin, Kuaishou, Tmall, Onion, VIPShop, Shopify etc.
Douyin, China’s version of TikTok, is a major key distribution channel for the company, on top of Tmall Global.
During last year’s Double 11 Shopping festival, EZZ achieved total revenue of AUD$5.9m, up 84 per cent yoy.
The increase was apparent across major platforms like Douyin, Kuaishou, and Tmall, and was driven by partnerships with influencers and livestreaming marketing.
However, the company is also cautious that its ability to maintain trade in China could be adversely affected by strained political and commercial relations between China and Australia.
“The company cannot confirm that these relations will improve in the short to medium term and cannot provide certainty going forward of its ability to trade in China.
“Further, should the USA’s protectionist policies lead to a weakening of China’s economic growth, the Chinese Government may impose restrictions or its Chinese citizen’s may reduce spending, either of which may impact the Company’s ability to sell its products into China.”
Aside from China, the company is active in its home market Australia and New Zealand, which made up about 14 per cent of its total sales at AUD$4.25m (US$2.7m) for the first half of FY25.
In total, EZZ had a revenue of AUD$30.3m (US$19.2m), up 40 per cent from AUD$21.7m (US$13.8) yoy during the first half of FY25.
Profit after tax was AUD$3.2m (US$2m), up from AUD$1.14m (US$725k) - nearly a 180 per cent increase yoy.
New products generated four per cent sales
On the other hand, the company launched eight products during the first half of FY25, which generated AUD$1.2m (US$762k) in sales, which is equivalent to four per cent of its total revenue.
The products were launched to address consumer demand for “advanced health and wellness solutions”, including EZZ Immune Defence, EZZ Propolis PRO 2000, EZZ Glutathione Health Support, EZZ Vitality Boost, and four functional food products targeting children and adults.
Its overall top three bestsellers were Lysine Growth Capsule, Bone Growth Chews, and High Strength DHA.
The company is also planning to bring products manufacturing process in-house within the next two to five years, having raised AUD$2.46m (US$1.56m).
